Search

Hear from an MSK social worker about developing body confidence after cancer treatment.

… Wednesday, July 31, 2019 Summary A person’s body image can change during and after cancer treatment. But support is available. One MSK social worker shares common concerns and how people can find healing and hope. Even after the surgery is over, the last chemotherapy infusion has been given, and the

According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.

… Tuesday, July 24, 2007 Steep Learning Curve Found According to a new study published online today in the Journal of the National Cancer Institute , prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by

In her 21 years at MSK, Tatanisha Peets has grown professionally and personally, working in Cytology, Pathology and now in Food and Nutrition services.

… Tuesday, February 22, 2022 In her 21 years at MSK,  Tatanisha Peets  has grown professionally and personally, working in Cytology, Pathology and now in Food and Nutrition services. Currently the Patient Experience Manager in Food and Nutrition Services, Tatanisha began her career at MSK as a secretary

Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, University of Washington School of Medicine, University of Michigan, and the Institute of Cancer Research Royal Marsden Hospital.

… Wednesday, July 6, 2016 Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber

MSK’s SPORE grant in leukemia has the potential to develop practice-changing approaches, evaluation, and management that may lead to improved patient outcomes for AML.

… Tuesday, September 7, 2021 The National Cancer Institute (NCI) recently awarded Memorial Sloan Kettering Cancer Center (MSK) with a prestigious Specialized Programs of Research Excellence (SPORE) grant for leukemia research. The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone

Memorial Sloan Kettering’s 42nd annual ceremony recognized graduates and award winners with a virtual ceremony.

… Thursday, May 20, 2021 Memorial Sloan Kettering’s 42nd annual Academic Convocation and Commencement ceremony, which took place on May 19, 2021, was held virtually for a second year due to the COVID-19 pandemic. Four members of MSK’s leadership team took to the stage in the Zuckerman Research Center,

At Memorial Sloan Kettering Cancer Center, we have now analyzed more than 50,000 samples in our prospective cohort with MSK-IMPACT™.

… Wednesday, February 24, 2021 At Memorial Sloan Kettering Cancer Center, we have now analyzed over 65,000 samples in our prospective cohort with MSK-IMPACT™ , our next-generation sequencing (NGS) platform, and are adding to that number every day. This is up 8000 from January this year, despite Covid-19

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder cancer (NMIBC).

… Monday, April 29, 2024 MSK Clinical Trials for Patients with BCG-Naïve, BCG-Exposed, and BCG-Unresponsive Bladder Cancer Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

… Friday, October 25, 2013 Summary Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients. Despite tremendous advances in medical research in recent decades, the number of new treatments that

Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1.

… Wednesday, February 8, 2012 Summary Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1. For the first time, Memorial Sloan Kettering investigators have revealed the three-dimensional shape of a protein called K2P1